Work

Effectiveness and Durability of the BNT162b2 KP.2 Vaccine Against COVID-19 Hospitalization and Emergency Department or Urgent Care Encounters in US Adults

Year: 2026

Type: article

Abstract: Vaccine effectiveness of BNT162b2 KP.2 vaccine against COVID-19 hospital admissions was 49% (95% CI, 30-63) and 45% (95% CI, 35-54) against emergency department/urgent care encounters (vs no KP.2 vaccine at <3 months). Protection persisted >90 days from vaccination with some waning. Vaccine effectiveness remained high regardless of prior COVID-19 vaccination and among older adults.

Source: Open Forum Infectious Diseases

DOI: 10.1093/ofid/ofag019

Authors: Sara Y Tartof, Timothy B Frankland, Jeff M Slezak, Bradley K Ackerson, Laura Puzniak

Institutions: Kaiser Permanente, Pfizer (United States)

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,053